4-Methylumbelliferyl a-L-Idopyranosiduronic Acid 2-Sulfate Disodium Salt

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-Methylumbelliferyl a-L-Idopyranosiduronic Acid 2-Sulfate Disodium Salt
• 英文别名: disodium;(2R,3S,4S,5R,6S)-3,4-dihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxy-5-sulfonatooxyoxane-2-carboxylate
• 化学式: C16H14Na2O12S
• 分子量: 476.3
• InChiKey: BGWMBPGUPUSUIU-CEWNINSASA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -8.47
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  200
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
  申请人：GREEN CROSS CORPORATION

  公开号：US10174299B2

  公开（公告）日：2019-01-08

  A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.

  本发明提供了一种包含重组iduronate-2-硫酸酯酶（IDS）的组合物和一种生产纯化重组IDS的方法。该 IDS 组合物的糖基化模式和甲酰基甘氨酸含量与 ELAPRASE® 不同，药效更优，比传统制剂更安全，因此可有效用于亨特综合征的治疗。
• Method of treating mucopolysaccharidosis type I or II
  申请人：Sangamo BioSciences, Inc.

  公开号：US10648001B2

  公开（公告）日：2020-05-12

  Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.

  核酸酶以及使用这些核酸酶将编码治疗性蛋白质（如酶）的序列插入细胞的方法，从而提供用于治疗和/或预防溶酶体贮积症的蛋白质或细胞疗法。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
  申请人：Sangamo BioSciences, Inc.

  公开号：US20160060656A1

  公开（公告）日：2016-03-03

  Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
• COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
  申请人：GREEN CROSS CORPORATION

  公开号：US20160145589A1

  公开（公告）日：2016-05-26

  A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
• US9896672B2
  申请人：——

  公开号：US9896672B2

  公开（公告）日：2018-02-20